Table 3.
CanSORT* (n = 477†)
|
BREAST-Q‡,§ (n = 451‖)
|
|||||
---|---|---|---|---|---|---|
n | Mean (95% CI) | P value | n | Mean (95% CI) | P value | |
Lump + WBI | 107 | 3.40 (3.14–3.67) | Referent | 104 | 60.00 (53.04–66.95) | Referent |
Lump + Brachy | 101 | 3.77 (3.54–4.00) | .007 | 98 | 66.95 (59.85–74.04) | .03 |
Lump alone | 74 | 3.80 (3.50–4.09) | .045 | 71 | 67.82 (57.48–78.17) | .12 |
Mast alone | 87 | 3.11 (2.83–3.40) | .06 | 82 | 59.27 (51.83–66.72) | .83 |
Mast + RT | 108 | 3.01 (2.77–3.25) | .006 | 96 | 50.24 (43.62–56.85) | .001 |
Abbreviations: CanSORT = Cancer Surveillance and Outcomes Research Team; CI = confidence interval; Lump alone = lumpectomy plus endocrine therapy alone; Lump + Brachy = lumpectomy plus brachytherapy; Lump + WBI = lumpectomy plus whole-breast irradiation; Mast alone = mastectomy alone; Mast + RT = mastectomy plus radiation therapy.
The final model for the CanSORT instrument was adjusted for Charlson Comorbidity Index.
Patients were included if they had ≥1 nonmissing response to the CanSORT instrument.
The final model for BREAST-Q Satisfaction with Breast was adjusted for race, Charlson Comorbidity Index, and patient-reported endocrine therapy.
CanSORT and BREAST-Q satisfaction scores were highly correlated with each other (Spearman coefficient = 0.8, P < .001).
Patients were included if they had ≥50% nonmissing responses; missing responses were assigned a value based on the mean of the nonmissing responses (in accordance with BREAST-Q scoring tables).